治疗前[18F]FDG PET/CT生物标志物预测转移性乳腺癌抗体药物偶联物疗效
回顾性双中心分析128例转移性乳腺癌患者,其中71例三阴性患者接受戈沙妥珠单抗(SG)、57例HER2低表达患者接受德曲妥珠单抗(T-DXd),治疗前[18F]FDG PET/CT测得的总代谢肿瘤体积(TMTV)和高肿瘤播散度(Dmax)与更短生存独立相关。
要点
- 治疗前高Dmax和高TMTV与SG组更短总生存独立相关。
- 治疗前高Dmax和高TMTV分别与T-DXd组更短无进展生存和总生存独立相关。
- 作者认为这些生物标志物有预后价值、可能优化治疗策略,但需更大研究验证。
核心结论
- 治疗前[18F]FDG PET/CT衍生的TMTV和Dmax在接受SG和T-DXd治疗的mTNBC和HER2低表达mBC患者中具有显著预后价值,可改善预后预测并可能优化治疗策略,值得临床使用,但需更大规模研究验证。
研究设计与样本
- 回顾性双中心分析,纳入128例转移性乳腺癌患者:71例三阴性mBC接受SG治疗,57例HR阳性和阴性HER2低表达mBC接受T-DXd治疗,均在治疗前接受[18F]FDG PET/CT扫描。
- 测量关键生物标志物包括最大标准化摄取值(SUVmax)、总代谢肿瘤体积(TMTV)和最大肿瘤播散度(Dmax),采用Cox模型和Kaplan-Meier曲线评估其对无进展生存(PFS)和总生存(OS)的预后价值。
主要发现
- 中位随访12.9个月;SG队列中位PFS为4.8个月、中位OS为8.9个月。
- SG队列中,高Dmax(HR 2.1,95%CI 1.1-4.3)和高TMTV(HR 2.9,95%CI 1.2-6.6)与更短OS独立相关。
- T-DXd队列中位PFS为5.8个月、中位OS为9.0个月。
- T-DXd队列中,高Dmax(HR 2.1,95%CI 1.2-3.9)与更短PFS独立相关,高TMTV(HR 2.4,95%CI 1.0-6.5)与更短OS独立相关。
临床怎么用
- 作者认为治疗前[18F]FDG PET/CT衍生的TMTV和Dmax具有预后价值,可改善预后预测并可能优化治疗策略,值得临床使用,但需更大规模研究验证。
局限性
- 原文为回顾性双中心分析。
- 原文结论指出需要更大规模研究来验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to evaluate the association between pretreatment [18F]FDG PET/CT-derived biomarkers and outcomes in metastatic breast cancer (mBC) patients treated with antibody-drug conjugates (ADCs) Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd). METHODS: A retrospective bicentric analysis was conducted on triple-negative mBC (mTNBC) patients treated with SG and HER2-low mBC patients treated with T-DXd, who underwent [18F]FDG PET/CT scans before therapy. Key biomarkers, including maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV) and maximum tumor dissemination (Dmax), were measured. Their prognostic value for progression-free survival (PFS) and overall survival (OS) was assessed using Cox models and Kaplan-Meier curves. RESULTS: 128 patients were included: 71 mTNBC treated with SG and 57 HR-positive and -negative HER2-low mBC treated with T-DXd. Median follow-up was 12.9 months. In the SG cohort, median PFS and OS were 4.8 and 8.9 months, respectively. High Dmax (HR 2.1, 95% CI 1.1-4.3) and high TMTV (HR 2.9, 95% CI 1.2-6.6) were independently associated with shorter OS. In the T-DXd cohort, median PFS and OS were 5.8 and 9.0 months, respectively. High Dmax (HR 2.1, 95% CI 1.2-3.9) and high TMTV (HR 2.4, 95% CI 1.0-6.5) independently correlated with shorter PFS and shorter OS, respectively. CONCLUSION: Pretreatment [18F]FDG PET/CT-derived biomarkers, namely TMTV and Dmax, have significant prognostic value in patients with mTNBC and HER2-low mBC treated with SG and T-DXd. These biomarkers improve prognostic prediction and may optimize treatment strategies, warranting their clinical use, but larger studies are needed to validate these findings.
引用
- Seban RD, Champion L, De Moura A, et al. Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 39373900. doi:10.1007/s00259-024-06929-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。